Medical Patent News

RSS

Skinvisible obtains Korean patent for polymer delivery system

Skinvisible, Inc. announced today that the South Korean patent office has granted a patent for Invisicare®, the company's polymer delivery system for topical dermatology products.

24 Mar 2010

Pluristem Therapeutics receives European Patent on core 3D cell expansion technology

Pluristem Therapeutics Inc. today announced that it has been granted a European Patent on its core 3D cell expansion technology. The granting of the European patent follows the issuance of several corresponding US patents as well as corresponding patents in ten additional jurisdictions.

23 Mar 2010

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.

23 Mar 2010

Texas jury returns binding verdict of invalidity on two Covidien's patent claims covering trocar seal technology

Applied Medical announced today that a United States District Court jury for the Eastern District of Texas returned a binding verdict of invalidity of two claims of a Covidien patent covering trocar seal technology.

23 Mar 2010

Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,668,598 covering the stimulation method used in the Urgent® PC Neuromodulation System.

23 Mar 2010

Covidien subsidiary wins patent infringement suit against Applied Medical Resources

Covidien, a leading global provider of healthcare products, today announced that a subsidiary of the Company won a patent infringement suit against Applied Medical Resources Corporation relating to certain of Applied Medical’s Kii™ and Universal® laparoscopic trocars.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Drug company fights for patent extension

The New York Times: The drug maker Medicines Company that makes the blood thinner called Angiomax, missed the application deadline to extend its patent back in 2000 by a day or two, depending on how you count.

20 Mar 2010

Providence receives U.S. patent for CPMMS

Providence today announces the receipt of a United States Patent for the Comprehensive Particulate Matter Measurement System (CPMMS) and the Methodology for its Use. Yousheng Zeng, PhD, PE, a principal of Providence, is the inventor of this system. Dr. Zeng explains, "Unlike current methods of monitoring air-borne particulate matter (PM), the CPMMS monitors the portion of PM that can reach and deposit in a human respiratory system."

19 Mar 2010

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that the U.S. Patent & Trademark Office has granted and will reissue the composition of matter patent for picoplatin as RE41209, replacing USPN 5,665,771 ('771 patent), on April 6, 2010. The reissue was applied for May 8, 2009, and, on March 17, 2010, the USPTO released the "Issue Notification" for the reissue application.

19 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1). Additional claims cover the surgical application of the NELL 1 (UCB-1) protein by several delivery agents.

18 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Patent applications continue to alter medical landscape to improve patient care

Over the past 40 years, more than 2,400 patents and patent applications-pioneering modern medicine with the devices and drugs that advance minimally invasive treatments-have been filed by members of the Society of Interventional Radiology.

17 Mar 2010

Shire receives Paragraph IV Notice Letter over generic INTUNIV ANDAs from Teva Pharmaceuticals

Shire plc, announces that it has received a Paragraph IV Notice Letter from Teva Pharmaceuticals USA, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1 mg, 2mg, 3 mg, and 4mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).

17 Mar 2010

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Quick-Med Technologies, Inc., a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that significantly adds to the current patent coverage for the Company's NIMBUS technology.

17 Mar 2010

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.

16 Mar 2010

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.

16 Mar 2010

AlloSource receives US patent for cleaning and disinfecting system

AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, has been awarded its first patent for a propriety tissue cleaning and disinfecting process called RICA.

16 Mar 2010

Medical Patent News

Skinvisible obtains Korean patent for polymer delivery system

Pluristem Therapeutics receives European Patent on core 3D cell expansion technology

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

Texas jury returns binding verdict of invalidity on two Covidien's patent claims covering trocar seal technology

Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Covidien subsidiary wins patent infringement suit against Applied Medical Resources

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Drug company fights for patent extension

Providence receives U.S. patent for CPMMS

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Patent applications continue to alter medical landscape to improve patient care

Shire receives Paragraph IV Notice Letter over generic INTUNIV ANDAs from Teva Pharmaceuticals

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

AlloSource receives US patent for cleaning and disinfecting system

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News